Hiding in Plain Sight? Homozygous Familial Hypercholesterolemia (HoFH) Live Webcast
HoFH is a genetic disorder of lipid metabolism resulting in severely elevated LDL-C and early onset ASCVD and increased CV events and mortality. Individuals with HoFH are typically less responsive, or even unresponsive, to standard lipid-lowering therapies such as statins and PCSK9 inhibitors, and may benefit from treatment modalities with other mechanisms of action.
This live CE/CME session focuses on the prevalence of both heterozygous and homozygous FH, the importance of FH screenings, and the benefits and limitations of available therapies for HoFH management. Multidisciplinary faculty of nationally-recognized FH experts will provide practical, evidence-based information regarding strategies to increase patient accessibility to newer lipid-lowering therapies.